Rajpura, Punjab - 140401, India Rajpura -2)Chitkara Innovation Incubator Foundation

(43) Publication Date: 10/01/2025

(19) INDIA

(22) Date of filing of Application :31/12/2024

(54) Title of the invention: COMBINATION THERAPY FOR OSTEOPOROSIS USING TRIBUTYRIN AND CALCITRIOL

:A61P0019100000, A61K0009000000, A61P0019080000, (51) International classification A61P0035020000, A61K0031593000

(86) International Application No :NA :NA Filing Date (87) International Publication No : NA (61) Patent of Addition to :NA Application Number :NA Filing Date (62) Divisional to Application :NA :NA Filing Date

Name of Applicant : NA

Address of Applicant : NA (72)Name of Inventor :

1)Dr. Samrat Chauhan

1)Dr. Salina Chaudai Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura -------

1)Chitkara University
Address of Applicant :Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla,

2)Parth Sharma

2) aru Shalma Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura -------

3)Sanchit Dhankhar Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National

Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura 4)Dr. Thakur Gurjeet Singh

Address of Applicant : Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura - 5)Somdutt Mujwar

Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura -------

6)Sanjana Mehta

Address of Applicant :Chitkara College of Pharmacy, Chitkara University, Chandigarh-Patiala National Highway, Village Jhansla, Rajpura, Punjab - 140401, India Rajpura

7)Monika Saini

(57) Abstract :

A novel composition for treating osteoporosis is disclosed, comprising Tributyrin and Calcitriol in specific concentration ranges, along with a sterile phosphate-buffered saline solvent, polysorbate 80, glycerin, benzyl alcohol, and pH-adjusting agents. This composition targets HDAC-6 and VDR pathways to enhance bone remodeling, decrease osteoclast activity, and mitigate osteoporosis symptoms. It is formulated for administration during the last 14 days of a 28-day protocol and is effective in increasing bone mineral density and improving serum biomarkers associated with bone health. The composition demonstrates superior efficacy compared to monotherapy approaches. Reference Fig 1

No. of Pages: 29 No. of Claims: 10